Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix Inc (BDSX) delivers innovative diagnostic solutions through advanced blood-based testing for lung disease and oncology. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and strategic partnerships.
Access real-time updates on earnings announcements, FDA clearances, clinical trial results, and biopharmaceutical collaborations. Our curated collection ensures you stay informed about critical developments in molecular diagnostics and precision medicine without needing to track multiple sources.
Key updates include:
• Financial performance reports
• Diagnostic test approvals
• Research partnership announcements
• Clinical study outcomes
Bookmark this page for streamlined access to verified Biodesix news. Combine regular monitoring with in-depth analysis of how these developments impact the diagnostic solutions landscape.
Biodesix (NASDAQ: BDSX) and Bio-Rad Laboratories have contributed to groundbreaking research findings from Friends of Cancer Research's ctMoniTR Project, published in Clinical Cancer Research. The study demonstrates a strong correlation between circulating tumor DNA (ctDNA) changes and treatment outcomes in cancer patients.
The research expands on previous findings, analyzing multiple solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors. The study utilized Bio-Rad's Droplet Digital™ PCR technology to detect ctDNA from patient samples.
Biodesix is currently exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD), with latest advancements to be presented at the upcoming American Association for Cancer Research Annual Meeting on April 28th, 2025.
Biodesix (NASDAQ: BDSX) reported strong financial results for Q4 and FY2024, with total revenue reaching $71.3 million, a 45% increase year-over-year. The company's performance was driven by a 43% growth in Lung Diagnostics revenue to $64.7 million and a 70% increase in Biopharma Services revenue to $6.6 million.
Q4 2024 revenue was $20.4 million, up 39% from the previous year. Gross margins improved to 78% for FY2024, up 5 percentage points from FY2023, primarily due to growth in Lung Diagnostic testing and workflow optimization. The company reported a net loss of $42.9 million for FY2024, an 18% improvement year-over-year.
Looking ahead, Biodesix provided FY2025 revenue guidance of $92-95 million. The company ended 2024 with $26.2 million in cash and cash equivalents, and subsequently amended its term loan facility with Perceptive Advisors to extend the availability of a $10 million Tranche C loan.
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has announced its participation in the TD Cowen 45th Annual Health Care Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on March 5, 2025.
The presentation is scheduled for 1:50 PM ET in Boston, MA. Investors and interested parties can access the live webcast and replay through the 'News & Events' section of the Investors page on biodesix.com.
Biodesix (NASDAQ: BDSX) has scheduled its Q4 and full-year 2024 financial results announcement for March 3, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Management will conduct a question-and-answer session for analysts, and a replay will be available on the company's investor website approximately two hours after the call concludes. Participants are recommended to join 15 minutes before the start time.
Biodesix (NASDAQ: BDSX) reported preliminary, unaudited results for Q4 and full-year 2024, showing significant growth across all segments. Total revenue reached an estimated $71.3 million for 2024, marking a 45% increase year-over-year, with Q4 revenue at $20.4 million, up 39%.
Lung Diagnostics, the company's primary segment, generated estimated revenue of $64.7 million for 2024 (up 43%) and $17.2 million for Q4 (up 34%), with test volumes reaching 54,300 for the year. Biopharma Services showed strong growth with $6.6 million in 2024 revenue (up 69%) and enters 2025 with $12.2 million under contract.
The company ended 2024 with cash and cash equivalents of $26.2 million, having focused on operational efficiencies and cost discipline throughout the year while expanding commercial, clinical, and R&D capabilities.
Biodesix (NASDAQ: BDSX) announced the publication of a new post-market clinical validation study in CHEST Pulmonary Journal for their Nodify CDT® blood-based lung nodule test. The study, involving 447 patients, reaffirmed the test's performance in detecting lung cancer through blood sample analysis of seven autoantibodies.
Key findings show that 33% of patients with cancerous nodules received diagnoses more than three months after detection when managed conventionally. The study demonstrated the test's high specificity, with very few benign nodules misclassified as high risk. When compared to PET scans in 222 patients, Nodify CDT® showed higher specificity with significantly fewer false positives.
The test is often used alongside Nodify XL2® as part of the Nodify Lung® Nodule Risk Assessment, helping identify appropriate diagnostic pathways for patients with indeterminate lung nodules.
Biodesix (NASDAQ: BDSX) reported Q3 2024 financial results with revenue growing 35% year-over-year to $18.2 million. Lung Diagnostic revenue increased 40% to $17.2 million, while Biopharmaceutical Services revenue decreased 17% to $1.0 million. The company achieved a gross profit margin of 77.0%, up from 76.1% in Q3 2023. Net loss improved by 6% compared to Q3 2023. Lung Diagnostic test volume grew 34% to 13,900 tests. The company reiterated its 2024 revenue guidance of $70-72 million and expects to achieve Adjusted EBITDA profitability in H2 2025.
Biodesix (Nasdaq: BDSX), a diagnostic solutions company specializing in lung disease, has announced its participation in three upcoming investor conferences in New York this November. CEO Scott Hutton and CFO Robin Cowie will attend the Craig-Hallum Alpha Select Conference on November 19, the Wolfe Research Healthcare Conference on November 20, and the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 21.
The company will deliver a presentation at the Canaccord event at 1:00 PM ET, which will be available via webcast on the Biodesix website's Investors section under 'News & Events'.
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its plans to release financial results for the third quarter ended September 30, 2024. The results will be published before trading begins on Friday, November 1, 2024. Following the release, Biodesix management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide a general business update.
Interested parties can register for the webcast through a provided link. Analysts wishing to participate in the question and answer session should use a separate link. A replay of the webcast will be made available on the company's investor website approximately two hours after the call concludes. Participants are advised to join the call 15 minutes before the start time.
Biodesix (Nasdaq: BDSX) announced new data presentation at CHEST 2024 Annual Meeting and launch of a complementary clinical study. The presentation will showcase the use of Nodify Lung® Nodule Risk Assessment in over 35,000 patients in real-world settings. Dr. Kathryn Long will present findings on reclassification rates for lung cancer risk, highlighting how the tests help clarify diagnostic plans.
Additionally, Biodesix introduced the CLARIFY study, a retrospective chart review of up to 4,000 patients, aimed at confirming the performance of Nodify CDT® and Nodify XL2® tests in diverse patient subgroups. This study will expand evidence supporting Nodify Lung testing's validation and utility.
CEO Scott Hutton emphasized the impact of Nodify Lung testing on lung nodule risk characterization over the past four years. The CHEST conference will also feature a presentation on patient impact and case studies by Drs. Sonali Sethi and D. Kyle Hogarth.
